Levomilnacipran Quiz

Q1: Levomilnacipran is classified as which type of antidepressant?

A) SSRI

B) SNRI

C) TCA

D) MAOI

Q2: Which of the following is the FDA-approved indication for Levomilnacipran?

A) Major depressive disorder (MDD)

B) Generalized anxiety disorder (GAD)

C) Bipolar disorder

D) Panic disorder

Q3: What is the starting dose of Levomilnacipran for treating MDD?

A) 20 mg once daily

B) 40 mg once daily

C) 50 mg once daily

D) 60 mg once daily

Q4: Which neurotransmitters does Levomilnacipran primarily affect?

A) Serotonin and norepinephrine

B) Dopamine and serotonin

C) GABA and glutamate

D) Acetylcholine and norepinephrine

Q5: Which side effect is most commonly associated with Levomilnacipran?

A) Nausea

B) Weight gain

C) Insomnia

D) Hyperhidrosis

Q6: Which serious adverse effect is a concern with Levomilnacipran, particularly at higher doses?

A) Hypertension

B) Hepatotoxicity

C) QT prolongation

D) Seizures

Q7: Levomilnacipran is contraindicated in patients with which of the following conditions?

A) Uncontrolled narrow-angle glaucoma

B) Mild hepatic impairment

C) Controlled diabetes

D) Hyperlipidemia

Q8: Which enzyme is primarily responsible for the metabolism of Levomilnacipran?

A) CYP3A4

B) CYP2D6

C) CYP1A2

D) CYP2C19

Q9: What is the black box warning associated with Levomilnacipran?

A) Increased risk of suicidal thoughts and behaviors in children, adolescents, and young adults

B) Risk of serotonin syndrome

C) Hepatotoxicity

D) Risk of hypertensive crisis

Q10: Which of the following drug interactions is important to consider when prescribing levomilnacipran?

A) Increased bleeding risk with NSAIDs

B) Serotonin syndrome with SSRIs

C) Reduced effectiveness with antacids

D) Increased sedation with antihistamines

Levomilnacipran (Fetzima) Medication